No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
170 |
4. Check minimum number of eventsNone |
170 |
5. Include endpointsNone |
170 |
6. Filter based on genotype QC (FinnGen only) |
170 |
Control definitions (FinnGen only)
- Control exclude
- H7_VISUALDISTBLIND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H54
- Name in latin
- Amblyopia non specificata oculorum amborum
Similar endpoints
↥List of similar endpoints to
Mild or no visual impairment, binocular
based on the number of shared cases.
Similar with more cases:
- Visual impairment including blindness (binocular or monocular)
- Visual disturbances and blindness
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1613 | 870 | 732 |
| Only index persons | 1433 | 791 | 642 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 42.74 | 48.39 | 35.96 |
| Only index persons | 44.24 | 49.24 | 38.09 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 170 | 114 | 56 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.02 |
| Median age at first event (years) | 52.78 | 49.21 | 60.03 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 151
- Matched controls
- 1511
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H54.3
ICD-10 Finland
Mild or no visual impairment, binocular
+∞
218.3
151
*
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
+∞
31.3
29
*
XCK00
NOMESCO Finland
Perimetry
15.7
27.7
47
42
H53.4
ICD-10 Finland
Visual field defects
283.1
24.4
24
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
8.2
19.8
48
81
XCD10
NOMESCO Finland
Electrophysiological examination of eye
25.8
19.0
26
12
XCW99
NOMESCO Finland
Other investigative procedure of eye
7.9
17.3
42
70
XCK10
NOMESCO Finland
Photography of fundus of eye
8.1
15.8
37
58
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.6
15.7
52
130
H53.1
ICD-10 Finland
Subjective visual disturbances
19.6
14.8
22
13
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
8.2
13.6
31
46
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
9.7
13.3
27
33
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
7.1
12.7
32
55
H35.5
ICD-10 Finland
Hereditary retinal dystrophy
+∞
12.7
12
*
H47.2
ICD-10 Finland
Optic atrophy
+∞
12.7
12
*
ZXA10
NOMESCO Finland
Bilateral
4.3
11.4
48
149
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
117.9
10.6
11
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
18.3
10.1
15
9
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.2
9.8
18
18
N03AG01
ATC
valproic acid; systemic, rectal
7.4
9.4
22
34
SPAT1229
SPAT
Assessment of need for aid
6.8
9.2
23
39
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.0
9.1
74
368
H54.7
ICD-10 Finland
Unspecified visual loss
53.1
8.8
10
*
H02AB06
ATC
prednisolone; systemic
2.8
8.7
87
491
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
6.6
8.7
22
38
R5210
NOMESCO Finland
Assessment of the improvements needed in the living environment
95.1
8.5
9
*
R3120
NOMESCO Finland
Training in mobility skills
95.1
8.5
9
*
H54.0
ICD-10 Finland
Blindness, binocular
+∞
8.4
8
*
WX140
NOMESCO Finland
Parabulbar anesthesy
11.0
8.2
15
15
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
18.5
8.2
12
7
TAB00
NOMESCO Finland
Lumbar puncture
7.8
7.7
17
24
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
84.0
7.5
8
*
H54.1
ICD-10 Finland
Severe visual impairment, binocular
+∞
7.3
7
*
CS494
NOMESCO Finland
Other visual field testing
10.8
7.2
13
13
ZXA00
NOMESCO Finland
Right side
2.8
7.0
52
237
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.9
6.9
22
51
H53.2
ICD-10 Finland
Diplopia
72.8
6.5
7
*
H53.0
ICD-10 Finland
Amblyopia ex anopsia
72.8
6.5
7
*
183
Kela drug reimbursment
Lamotrigin and topiramate
28.0
6.3
8
*
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
+∞
6.3
6
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
5.7
6.2
17
33
H52.2
ICD-10 Finland
Astigmatism
13.3
6.2
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
12
12
10.68
10.56
1.2
1.0
—
—
—
0
0
104
603
2.87
10.12
7.5
6.4
1.2
1.2
mmol/l
1.88
90
513
118
733
2.99
10.05
7.9
4.4
6.7
6.5
mmol/l
0.53
111
674
92
512
2.74
9.51
4.7
4.4
35.7
35.8
g/l
0.01
87
486
27
76
4.03
8.82
5.3
4.7
0.2
1.8
mmol/l
0.81
19
58
94
544
2.63
8.77
7.7
6.0
1.2
1.2
mmol/l
1.66
86
494
46
184
3.06
8.77
1.9
1.9
—
—
—
0
0
73
395
2.49
7.58
3.3
2.2
49.0
57.2
u/l
1.70
62
369
60
296
2.59
7.57
2.1
2.0
—
—
—
0
0
7
0
+∞
7.34
1.0
0.0
—
—
—
0
0
33
131
2.88
6.25
5.1
5.4
0.9
1.0
mmol/l
0.08
27
100
78
465
2.25
6.21
2.1
1.9
98.0
96.4
pmol/l
0.09
44
236
31
124
2.83
5.77
1.8
1.8
—
—
—
0
0
44
211
2.46
5.72
4.0
3.4
251.0
95.8
ng/l
0.42
31
147
10
17
6.19
5.69
1.2
1.1
—
—
—
0
0
10
17
6.19
5.69
1.2
1.1
—
—
—
0
0
84
538
2.11
5.38
2.6
2.5
75.4
76.2
nmol/l
0.08
76
487
34
151
2.56
5.16
5.8
5.9
1.0
1.1
mmol/l
2.20
34
139
23
83
3.05
5.12
7.6
6.5
24.3
24.9
mmol/l
0.39
23
83
96
656
2.06
5.07
7.1
5.7
9.1
12.0
umol/l
2.66
86
629
18
57
3.41
4.92
1.7
1.6
—
—
—
0
0
30
130
2.59
4.77
1.9
1.8
—
—
—
0
0
106
766
2.02
4.63
11.7
9.3
4.4
4.0
e9/l
1.12
96
670
128
995
2.16
4.52
9.9
6.7
80.4
81.8
u/l
0.15
122
932
15
45
3.56
4.44
1.7
2.0
—
—
—
0
0
9
12
7.85
4.41
1.1
1.2
—
—
—
0
0
14
42
3.54
4.14
1.9
1.8
—
—
—
0
0
25
106
2.59
4.14
5.9
5.7
124.5
120.6
g/l
0.39
25
101
65
410
1.95
4.09
5.2
3.9
26.2
22.8
ng/l
0.27
47
273
58
355
1.96
3.96
4.5
3.1
0.5
0.3
e6/l
0.52
41
258
143
1189
2.28
3.85
19.2
11.4
83.5
84.7
ml/min/173m2
0.25
120
948
25
111
2.47
3.77
1.9
2.2
0.2
0.2
g/l
0.31
25
106
123
979
1.93
3.58
5.1
3.9
14.9
11.3
mm/h
1.42
110
902
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
11
31
3.72
3.54
2.4
2.4
0.4
0.3
u/ml
—
5
21
66
435
1.85
3.54
4.7
3.3
—
—
—
0
0
52
319
1.91
3.47
2.5
2.0
3.1
3.2
mg/l
0.17
44
281
49
296
1.92
3.42
3.1
3.5
1773.6
1362.3
ng/l
0.30
44
247
46
275
1.92
3.30
2.3
1.9
1.3
1.3
mg/l
0.03
33
210
47
286
1.89
3.19
2.9
2.9
324.6
7618.3
umol/l
1.84
42
247
27
136
2.17
3.06
24.1
20.7
1.1
1.3
inr
—
5
18
111
878
1.76
3.04
5.2
2.8
50.2
40.7
u/l
0.61
102
831
30
163
2.02
2.80
2.7
2.1
2.4
2.4
g/l
0.05
25
149
45
283
1.80
2.72
1.9
1.4
15.1
22.4
nmol/l
3.34
40
249
28
150
2.04
2.72
4.5
2.7
5.4
8.7
umol/l
1.18
23
131
36
211
1.90
2.71
3.6
3.0
0.4
0.9
e6/l
1.56
19
122
136
1162
1.85
2.65
6.5
5.2
40.4
39.3
mmol/mol
0.54
123
1093
150
1326
2.12
2.60
22.8
12.1
23.6
21.3
mg/l
0.37
134
1020
82
618
1.63
2.52
4.3
3.8
—
—
—
0
0
19
90
2.25
2.50
1.5
1.5
—
—
—
0
0
16
71
2.38
2.43
1.2
1.2
—
—
—
0
0
50
335
1.70
2.41
1.3
1.3
0.9
1.7
u/ml
—
6
82
9
29
3.22
2.26
1.4
1.1
—
—
—
0
0
9
29
3.22
2.26
1.4
1.1
—
—
—
0
0
12
48
2.61
2.24
1.5
2.1
—
—
—
0
0
58
414
1.61
2.16
2.9
2.8
2.3
2.4
mmol/l
0.73
51
364
121
1027
1.62
2.12
5.5
3.9
14.5
14.6
pmol/l
0.15
106
936
7
20
3.60
2.08
1.0
1.2
—
—
—
0
0
6
15
4.10
2.05
1.2
1.2
—
—
—
0
0
7
21
3.43
1.98
1.1
1.0
—
—
—
0
0
9
33
2.82
1.96
1.4
2.5
0.0
0.0
g/l
—
9
33
24
137
1.88
1.96
9.1
6.9
—
—
—
0
0
32
201
1.73
1.92
2.7
2.4
2.5
2.4
mmol/l
0.28
27
170
7
22
3.27
1.90
1.1
1.4
—
—
—
0
0
6
17
3.62
1.85
8.2
4.2
25.3
23.8
nmol/l
—
6
17
5
13
3.93
1.72
1.4
1.5
—
—
—
0
0
33
216
1.65
1.71
1.9
1.6
982.9
1148.8
nmol/l
0.53
23
174
31
200
1.67
1.69
3.8
3.2
2.0
2.5
e6/l
0.19
14
111
6
19
3.23
1.67
1.2
1.2
—
—
—
0
0
138
1239
1.60
1.61
6.4
4.6
1.9
1.8
mu/l
0.05
126
1136
14
72
2.03
1.54
7.7
5.9
24.7
24.6
mmol/l
0.05
14
65
5
15
3.40
1.53
1.2
1.7
—
—
—
0
0
6
21
2.92
1.52
1.0
1.0
—
—
—
0
0
9
37
2.51
1.50
2.0
1.2
—
—
—
0
0
9
39
2.38
1.45
1.7
1.7
—
—
—
0
0
7
29
2.47
1.41
1.3
1.2
—
—
—
0
0
74
600
1.41
1.39
3.8
2.6
103.7
90.6
ug/l
0.21
67
559
6
23
2.67
1.38
1.5
1.4
—
—
—
0
0
14
76
1.92
1.34
3.4
2.3
8.4
13.0
nmol/l
—
9
71
17
107
1.65
1.04
3.4
3.8
—
—
—
0
0
103
912
1.33
1.01
3.6
3.5
—
—
—
0
0
6
28
2.18
0.92
1.3
1.5
—
—
—
0
0
6
28
2.18
0.92
1.0
1.6
—
—
—
0
0
6
30
2.04
0.88
1.7
1.6
—
—
—
0
0
8
44
1.86
0.87
1.3
1.1
—
—
—
0
0
156
1490
1.57
0.83
32.5
18.4
132.8
134.3
g/l
0.69
156
1471
8
48
1.70
0.80
1.3
1.4
—
—
—
0
0
5
25
2.03
0.73
1.2
1.9
—
—
—
0
0
135
1267
1.32
0.72
5.1
4.5
2.7
2.8
mmol/l
0.51
126
1176
31
244
1.33
0.67
1.5
1.7
414.7
472.8
pmol/l
0.69
25
210
5
28
1.81
0.66
1.2
1.2
—
—
—
0
0
10
62
1.65
0.66
1.8
2.0
—
—
—
0
0
132
1242
1.28
0.64
5.3
4.1
6.0
5.9
mmol/l
0.59
121
1145
131
1232
1.28
0.63
24.9
13.2
39.0
39.6
%
0.38
96
955
41
339
1.28
0.63
1.7
1.6
1.5
1.3
mmol/l
0.66
33
295
0
20
0.00
0.61
0.0
3.0
—
89.0
—
0
20
0
22
0.00
0.59
0.0
3.0
—
90.6
—
0
13
12
81
1.52
0.59
1.0
1.0
—
—
—
0
0
71
630
1.22
0.58
4.7
3.8
0.0
0.0
estimate
0.00
11
118
6
35
1.74
0.58
1.2
1.9
—
—
—
0
0
6
35
1.74
0.58
1.7
1.9
—
—
—
0
0
8
123
0.63
0.57
1.5
1.6
—
—
—
0
0
6
39
1.56
0.53
1.5
1.4
—
—
—
0
0
20
254
0.76
0.50
1.4
1.4
—
—
—
0
0
126
1193
1.22
0.49
4.1
3.7
1.3
1.2
mmol/l
0.58
113
1102
131
1249
1.21
0.45
4.5
4.1
4.5
4.7
mmol/l
0.88
123
1170
69
626
1.17
0.42
6.7
5.3
0.0
0.0
estimate
0.00
11
122
5
32
1.58
0.42
1.4
2.5
—
—
—
0
0
8
58
1.40
0.42
3.3
3.9
60.8
48.9
%
—
8
58
130
1242
1.20
0.41
4.5
4.0
1.4
1.5
mmol/l
1.62
119
1153
39
343
1.18
0.35
4.6
3.8
0.0
0.0
estimate
—
10
116
68
625
1.15
0.34
4.8
3.8
0.0
0.0
estimate
—
10
121
7
54
1.31
0.31
1.7
2.3
—
—
—
0
0
8
62
1.30
0.28
2.5
3.1
1.4
1.3
%
—
8
62
45
492
0.88
0.26
5.0
3.8
—
—
—
0
0
5
37
1.36
0.23
1.8
2.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
29
264
1.12
0.17
3.9
4.9
1.7
3.3
ug/l
0.65
23
235
7
86
0.81
0.15
1.0
1.3
—
—
—
0
0
8
99
0.80
0.14
1.5
1.5
—
—
—
0
0
9
108
0.82
0.13
2.4
1.8
—
—
—
0
0
25
232
1.09
0.10
1.4
1.3
1.8
9.8
u/ml
—
5
96
12
134
0.89
0.09
2.3
2.0
—
—
—
0
0
21
198
1.07
0.05
1.8
2.1
—
—
—
0
0
23
219
1.06
0.04
1.9
2.3
—
—
—
0
0
20
208
0.96
0.02
4.0
4.3
29.6
22.5
%
—
7
98
31
306
1.02
0.00
1.4
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
1424.8
—
0
5
0
8
0.00
0.00
0.0
1.1
—
58.8
—
0
8
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
10.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_MILDVISIMPBINOC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_MILDVISIMPBINOC | 1.814 [1.3, 2.54] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.541 |
During the follow-up period (1.1.1998 — 31.12.2019), 182 out of 791 females with H7_MILDVISIMPBINOC died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_MILDVISIMPBINOC | 2.239 [1.54, 3.26] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 685 males with H7_MILDVISIMPBINOC died.
Mortality risk
Mortality risk for people of age
years, who have H7_MILDVISIMPBINOC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.192% | 0.38% |
| 5 | 1.068% | 2.285% |
| 10 | 2.739% | 5.686% |
| 15 | 5.429% | 11.097% |
| 20 | 9.766% | 18.066% |
Relationships between endpoints
↥Index endpoint: H7_MILDVISIMPBINOC – Mild or no visual impairment, binocular
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data